Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Usmani, Saad
Item TypeName
Concept Angiogenesis Inhibitors
Concept Poly(ADP-ribose) Polymerases
Concept Histone Deacetylase Inhibitors
Concept Enzyme Inhibitors
Academic Article Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Academic Article Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Academic Article NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Academic Article Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Academic Article HSP90 inhibitors as therapy for multiple myeloma.
Academic Article American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Academic Article Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Academic Article Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Academic Article Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Academic Article Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Academic Article How to Treat High-Risk Myeloma at Diagnosis and Relapse.
Concept Poly (ADP-Ribose) Polymerase-1
Concept Proteasome Inhibitors
Academic Article Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Academic Article Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Academic Article Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Search Criteria
  • Poly ADP ribose Polymerase
  • Inhibitors